Derma Sciences, Inc. Reports Third Quarter Financial and Operating Results; End-of-Phase 2 Meeting Set with FDA

PRINCETON, N.J.--(BUSINESS WIRE)--Derma Sciences, Inc. (Nasdaq: DSCI), a medical device and pharmaceutical company focused on advanced wound care, today reported financial and operating results for the three and nine months ended September 30, 2011. Highlights of the third quarter of 2011 and recent weeks include:

•Net sales were $15.8 million, up 5% over the prior-year third quarter •Quarterly net loss increased $242,919 to $789,257 from $546,338 in the prior year as planned